TORONTO (Reuters) - Aeterna Zentaris Inc reported a quarterly loss on Wednesday, hurt by lower sales and royalties and falling manufacturing margins.
The biopharmaceuticals company said it lost C$14.5 million ($11.3 million), or 27 Canadian cents a share, during its fourth quarter, compared with a loss of C$13.6 million, or 26 Canadian cents a share, for the same time in the previous year.
Excluding a number of items including income tax adjustments, the company said it lost C$13.5 million, or 27 Canadian cents a share.
Revenue dropped 29.3 percent to C$7.2 million.
Analysts on average were expecting a loss of 26 Canadian cents a share and revenue of C$9.6 million, according to Reuters Estimates.
Reporting by Scott Anderson; Editing by Steve Orlofsky